| | | PUBLICATIONS (Ranked by impact factor of the journal) |
Live Imaging of Adult Neural Stem Cell Behavior in the Intact and Injured Zebrafish Brain
Investigators used repetitive imaging to follow single stem cells in the intact and injured adult zebrafish telencephalon in vivo and found that neurons are generated by both direct conversions of stem cells into postmitotic neurons and via intermediate progenitors amplifying the neuronal output. [Science] Abstract
Presenilin 1 Is Necessary for Neuronal, but Not Glial, EGFR Expression and Neuroprotection via γ-Secretase-Independent Transcriptional Mechanisms
Researchers showed that absence of presenilin 1 (PS1) results in dramatic decrease of neuronal epidermal growth factor receptor (EGFR) and that PS1-null (PS1−/−) brains have reduced amounts of this receptor. PS1−/− cortical neurons contained little EGFR and showed no epidermal growth factor-induced survival signaling or protection against excitotoxicity, but exogenous EGFR rescued both functions even in absence of PS1. [FASEB J]
Abstract
E-Cadherin Enhances Neuregulin Signaling and Promotes Schwann Cell Myelination
To determine whether E-cadherin plays a regulatory role during Schwann cell myelination, the authors investigated the effects of E-cadherin deletion and over-expression in Schwann cells. [Glia] Abstract
Oncostatin M-Dependent Mcl-1 Induction Mediated by JAK1/2-STAT1/3 and CREB Contributes to Bioenergetic Improvements and Protective Effects against Mitochondrial Dysfunction in Cortical Neurons
Scientists tested the hypothesis that oncostatin M (OSM) may confer neuronal resistance against 3-nitropropionic acid (3-NP), a plant toxin that irreversibly inhibits the complex II of the mitochondrial electron transport chain, and characterized the underlying molecular mechanisms. They found that OSM preconditioning dose- and time-dependently protected cortical neurons against 3-NP toxicity. [Biochim Biophys Acta]
Abstract
Prevention of Human Dopaminergic Neurodegeneration in an Astrocytes Co-Culture System allowing Endogenous Drug Metabolism
Researchers grew an intricate network of human dopaminergic neurons on top of a dense layer of astrocytes. In these co-cultures, 1-methyl-4-phenyl-tetrahydropyridine was metabolized to 1-methyl-4-phenyl-pyridinium by the glial cells, and the toxic metabolite was taken up through the dopamine transporter into neurons. [Br J Pharmacol] Abstract
Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells
A small-molecule selective blocker for Kv1.3, Psora-4, was added to the differentiation medium of cultured mouse neural progenitor cells (NPCs) to assess its effect on NPC differentiation efficiency. [CNS Neurosci Ther] Abstract
Ezh2 Maintains Retinal Progenitor Proliferation, Transcriptional Integrity, and the Timing of Late Differentiation
Scientists showed that during retinal development in mouse, there are dynamic patterns of expression of the polycomb repressive complex 2 catalytic subunit EZH2 in retinal progenitors and some differentiated cells, as well as dynamic changes in the histone modification H3K27me3. [Dev Biol] Abstract
Altered Proliferative Ability of Neuronal Progenitors in PlexinA1 Mutant Mice
Earlier studies have highlighted the importance of neuropilin 1 (Nrp1) and Nrp2 in interneuron migration, therefore scientists assessed the role of PlexinA1 in this process. They observed significantly fewer cells expressing the interneuron markers Gad67 and Lhx6 in the cortex of PlexinA1-/- mice compared to wild-type littermates at E14.5 and E18.5. [J Comp Neurol] Abstract
Plexin-B3 Suppresses Excitatory and Promotes Inhibitory Synapse Formation in Rat Hippocampal Neurons
Researchers demonstrated that Plexin-B2 and Plexin-B3 are present in dendrites, but do not localize in synapses. They found that overexpression of all B-plexins leads to decreased volume of excitatory synapses, and at the same time Plexin-B1 and Plexin-B3 promote inhibitory synapse assembly. [Exp Cell Res] Abstract
Glucagon-Like Peptide-1 Regulates Mitochondrial Biogenesis and Tau Phosphorylation against Advanced Glycation End Product-Induced Neuronal Insult: Studies In Vivo and In Vitro
Investigators demonstrated glucagon-like peptide-1 receptor agonists could inhibit oxidative stress and repair the mitochondrial damage in addition to decreasing tau hyperphosphorylation in PC12 cells treated with advanced glycation end products. [Neuroscience] Abstract
Let7a Involves in Neural Stem Cell Differentiation Relating with TLX Level
The authors investigated whether microRNA-Let7a (Let7a) regulates neural stem cell (NSC) differentiation by targeting the nuclear receptor TLX, which is an essential regulator of NSC self-renewal, proliferation and differentiation. [Biochem Biophys Res Commun] Abstract
|
| | | REVIEWS |
Toward Stem Cell-Based Phenotypic Screens for Neurodegenerative Diseases
Phenotypic screening in neurons and glia derived from patients is now conceivable through unprecedented developments in reprogramming, transdifferentiation, and genome editing. The authors outline progress in this nascent field, but also consider the formidable hurdles to identifying robust, disease-relevant and screenable cellular phenotypes in patient-derived cells. [Nat Rev Neurol]
Abstract
Glia Disease and Repair—Remyelination
The authors review the biology of remyelination, including the cells and signals involved; describe when remyelination occurs and when and why it fails and the consequences of its failure; and discuss approaches for therapeutically enhancing remyelination in demyelinating diseases of both children and adults, both by stimulating endogenous oligodendrocyte progenitor cells and by transplanting these cells into demyelinated brain. [Cold Spring Harb Perspect Biol]
Abstract
Commonalities in Immune Modulation between Mesenchymal Stem Cells (MSCs) and Neural Stem/Precursor Cells (NPCs)
Increasing evidence suggests that stem cells, other than MSCs, are also capable of immunomodulation. NPCs have been among the first stem cells showing immunomodulatory properties and nowadays represent one the most studied and promising stem cell subtype in still uncurable acute and chronic inflammatory neurological disorders. [Immunol Lett] Abstract
Visit our reviews page to see a complete list of reviews in the neural cell research field.
|
| | | INDUSTRY NEWS |
vTv Therapeutics Initiates Pivotal Phase III Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
vTv Therapeutics LLC announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy), vTv’s Phase III placebo controlled trial of azeliragon, an oral antagonist of the receptor for advanced glycation endproducts for treatment of mild Alzheimer’s disease. [vTv Therapeutics LLC]
Press Release
Oncolytics Biotech® Inc. Announces Phase I Study in Pediatric Patients with Brain Tumors
Oncolytics Biotech Inc. announced that following submission to the U.S. Food and Drug Administration for review, the investigational new drug application containing the protocol titled “MC1472: Phase I Study of Replication Competent Reovirus in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors” is now active. [Oncolytics Biotech Inc.]
Press Release
Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer
Alcyone Lifesciences, Inc. and DNAtrix Inc. have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone’s MEMS Cannula targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix’s lead product for the treatment of the most aggressive form of brain cancer, glioblastoma. [Alcyone Lifesciences, Inc. (PR Newswire Association LLC)]
Press Release
Aphios Granted United States Patent for Alzheimer’s Disease Treatment
Aphios Corporation announced that it was granted United States Patent No. 9,034,347 directed to the treatment of neurodegenerative diseases such as Huntington’s disease, Parkinson’s disease, Down syndrome and Alzheimer’s disease. [Aphios Corporation] Press Release
Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases
Denali Therapeutics Inc., a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced that it has launched with an initial investment commitment of $217 million. [Denali Therapeutics Inc.] Press Release
Yale Scientist Receives Sanberg Award from American Society of Neural Therapy and Repair
The American Society of Neural Therapy and Repair has awarded the 2015 Bernard Sanberg Memorial Award for Brain Repair to John D. Elsworth, PhD, senior research scientist in psychiatry at Yale School of Medicine. [Yale School of Medicine] Press Release
|
|
